Seamless phase II/III combination study through response adaptive randomization

Journal of Biopharmaceutical Statistics

Volumn 17, Issue 6, 2007, Pages 1177-1187

  Wang, Lin ^a   Cui, Lu ^b  

^a SANOFI   (France)

^b EISAI INC   (United States)

Author keywords

Adaptive randomization; Clinical trials; Type I error rate

Indexed keywords

CLINICAL RESEARCH; CLINICAL STUDY; COMPUTER SIMULATION; CONFERENCE PAPER; MATHEMATICAL ANALYSIS; MEDICAL ERROR; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 36249017961     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400701645322     Document Type: Conference Paper

References (28)

1. Bauer, P., Kieser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 18:1833-1848.
2. Chen, Y. H., DeMets, D. L., Lan, K. K. G. (2004). Increasing the sample size when the unblended interim result is promising. Statistics in Medicine 23:1023-1038.
3. Chow, S., Chang, M. (2006). Adaptive Design Methods in Clinical Trials. Boca Raton, Florida: Chapman & Hall/CRC.
4. Coad, D., Rosenberger, W. (1999). A comparison of the randomized play-the-winnder and the trialgular test for clinical trials with binary responses. Statistics in Medicine 18:761-769.
5. Cui, L., Hung, H., Wang, S. (1997). Impact of changing sample size in a group sequential clinical trial. ASA Proceedings of the Biopharmaceutical Section, pp. 52-57.
6. Cui, L., Hung, H., Wang, S. (1999). Modification of sample size in group sequential clinical trial. Biometrics 55:853-857.
7. Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., Phinheiro, J. (2006). Adaptive design in clinical drug development - An executive summary of the PhRMA Working Group (with discussions). Journal of Biopharmaceutical Statistics 16:275-283.
8. Gould, A. L. (2001). Sample size re-estimation: recent developments and practical considerations. Statistics in Medicine 20:2625-2643.
9. Gould, A. L., Shih, W. J. (1992). Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Communications in Statistics: Theory and Methods 21:2833-2853.
10. Hartung, J., Knapp, G. (2003). A new class of completely self-designing clinical trials. Biometrical Journal 45:3-19.
11. Hung, H. M. J., Cui, L., Wang, S. J., Lawrence, J. (2005). Adaptive statistical analysis following sample size modification based on interim review of efficacy size. Journal of Biopharmaceutical Statistics 15:693-706.
12. Inoue, L., Thall, P., Berry, D. (2002). Seamless expanding a randomized Phase II trial to Phase III. Biometrics 58:823-831.
13. Ivanova, A., Flournoy, N. (2001). A birth and death urn for ternary outcomes: Stochastic processes appled to urn models. In: Charalambides, C. et al., eds. Probability and Statistical Models with Applications. Boca Raton, Florida: Chapman and Hall/CRC Press, pp. 583-600.
14. Jennison, C., Turnbull, B. (2003). Mid-course sample size modification in clinical trials based on the observed treatment effect. Statistics in Medicine 22:971-993.
15. Jennison, C., Turnbull, B. (2006). Efficient group sequential designs when there are several effect sizes under consideration. Statistics in Medicine 22:971-993.
16. Kelly, P., Stallard, N., Todd, S. (2005). An adaptive group sequential design for Phase II/III clinical trials that select a single treatment from several. Journal of Biopharmaceutical Statistics 15:641-658.
17. Lan, K. K. G., Trost, D. C. (1997). Estimation of parameters and sample size re-estimation. ASA Proceedings of the Biopharmaceutical Section, pp. 48-51.
18. Lehmacher, W., Wassmer, G. (1999). Adaptive sample size calculations in group sequential trials. Biometrics 55:1286-1290.
19. Liu, Q., Chi, G. Y. H. (2001). On sample size and inference for two-stage adaptive designs. Biometrics 57:172-177.
20. Liu, Q., Pledger, G. (2005). Phase II and III combination designs to accelerate drug development. Journal of American Statistical Association 100:493-502.
21. Muller, H. H., Schafer, H. (2001). Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and classical group sequential approaches. Biometrics 57:886-891.
22. Posch, M., Bauer, P., Brannath, W. (2003). Issues in designing flexible trials. Statistics in Medicine 22:953-969.
23. Proschan, M. A., Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics 51:1315-1324.
24. Rosenberger, W., Lachin, J. (2002). Randomization in Clinical Trials. New York: John Wiley and Sons.
25. Shen, Y., Fisher, L. D. (1999). Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics 55:190-197.
26. Shun, Z., Yuan, W., Brady, W., Hsu, H. (2001). Type I error in sample size re-estimation based on observed treatment difference. Statistics in Medicine 20:497-513.
27. Tsiatis, A., Mehta, C. (2003). On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 90:367-378.
28. Wei, L. J., Smythe, R. T., Lin, D. Y., Park, T. S. (1990). Statistical inference with datadependent treatment allocation rules. Journal of the American Statistical Association 85, 409:156-162.